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Abstract
Escape from the host immune system is essential for intracellular pathogens. The adenoviral protein E3-14.7K (14.7K) is
known as a general inhibitor of tumor necrosis factor (TNF)-induced apoptosis. It efficiently blocks TNF-receptor 1 (TNFR1)
internalization but the underlying molecular mechanism still remains elusive. Direct interaction of 14.7K and/or associated
proteins with the TNFR1 complex has been discussed although to date not proven. In our study, we provide for the first
time evidence for recruitment of 14.7K and the 14.7K interacting protein optineurin to TNFR1. Various functions have been
implicated for optineurin such as regulation of receptor endocytosis, vesicle trafficking, regulation of the nuclear factor kB
(NF-kB) pathway and antiviral signaling. We therefore hypothesized that binding of optineurin to 14.7K and recruitment of
both proteins to the TNFR1 complex is essential for protection against TNF-induced cytotoxic effects. To precisely dissect
the individual role of 14.7K and optineurin, we generated and characterized a 14.7K mutant that does not confer TNF-
resistance but is still able to interact with optineurin. In H1299 and KB cells expressing 14.7K wild-type protein, neither
decrease in cell viability nor cleavage of caspases was observed upon stimulation with TNF. In sharp contrast, cells
expressing the non-protective mutant of 14.7K displayed reduced viability and cleavage of initiator and effector caspases
upon TNF treatment, indicating ongoing apoptotic cell death. Knockdown of optineurin in 14.7K expressing cells did not
alter the protective effect as measured by cell viability and caspase activation. Taken together, we conclude that optineurin
despite its substantial role in vesicular trafficking, endocytosis of cell surface receptors and recruitment to the TNFR1
complex is dispensable for the 14.7K-mediated protection against TNF-induced apoptosis.
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Introduction
Tumor necrosis factor (TNF) is a highly pleiotropic cytokine
with critical functions in diverse cellular events ranging from
proliferation to inflammation and induction of apoptosis [1]. It is
furthermore of outstanding importance for the eradication of
intracellular pathogens. Vice versa, intracellular pathogens obviously
require sophisticated strategies to escape from TNF-mediated
cytotoxic effects and the host immune system. Several proteins
encoded in the early region 3 (E3) of adenoviruses facilitate
infection or promote persistence in hosts by regulating the activity
of cytokines [2]. Especially E3-14.7K (14.7K) efficiently prevents
TNF-mediated cytotoxicity by blocking TNF-receptor 1 (TNFR1)
internalization [3,4].
Under physiological circumstances, TNFR1 is internalized
upon ligand binding via clathrin-coated vesicles within minutes
[5]. In earlier studies, we provided evidence that TNFR1
internalization not only functions as a ‘‘switch-off’’ for signaling
events by receptor degradation and/or recycling [6]. In fact,
TNFR1 internalization constitutes a conditio sine qua non for
assembly of the death inducing signaling complex (DISC), a
crucial event followed by caspase activation and induction of
apoptotic cell death. Interestingly, activation of the proinflamma-
tory and antiapoptotic nuclear factor kB (NF-kB) pathway is
independent from TNFR1 internalization [4]. To date, the
molecular mechanism of 14.7K mediated TNF-resistance is
poorly understood, especially as several attempts to demonstrate
interaction of 14.7K with TNFR1 complex failed [4,7].
Potentially, intracellular binding proteins provide an indirect
linkage between 14.7K and TNFR1. In a previous study, four
14.7K interacting proteins were identified in a yeast-two-hybrid
screen, including inhibitor of kappa B kinase c (IKKc), the small
GTPase RagA, apoptosis inducing factor (AIF) and optineurin
(OPTN) [8,9]. Beside the role of the latter in wide-angle glaucoma
[10], optineurin is recruited to the TNFR1 complex, where it
negatively regulates the NF-kB pathway [11], alters intracellular
traffic of vesicels [12] and impairs endocytosis of cell surface
receptors [13]. Regarding the properties of this molecule,
optineurin potentially represents the molecular link between
14.7K and the TNFR1 complex. This led us to the hypothesis
that protection against TNF-mediated cytotoxic effects requires
recruitment of both optineurin and 14.7K to TNFR1 complex.
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To analyze the functional significance of 14.7K interaction with
optineurin we took advantage of a previously characterized 14.7K
mutant. A C-terminal point mutation (C119S, designated
14.7K PM) affects structural integrity and abolishes protection
against TNF-mediated cytotoxic effects [4,14].
We demonstrate in this study that 14.7K PM not only exhibits
loss of protection against TNF-mediated cytotoxic effects, but is
also defective in optineurin binding. Whether susceptibility is due
to functional defects of 14.7K PM caused by the point mutation or
absence of optineurin remained elusive and required generation of
14.7K mutants with intact optineurin binding. Our results suggest
that 14.7K-mediated TNF-resistance is not associated with
absence or presence of optineurin, but critically depends on
expression of 14.7K wilde-type protein. Taken together, we
conclude that optineurin binds 14.7K as part of the TNFR1
complex, but is despite its role in vesicular trafficking and
endocytosis of cell surface receptors dispensable for the 14.7K-
mediated protection against TNF-induced cytotoxicity.
Results
The protective effect of 14.7K against TNF-mediated cytotox-
icity has been demonstrated in several studies [7,14,15] and was
attributed to impaired TNFR1 internalization and subsequent
absence of death inducing signaling complex (DISC) formation
[4]. However, the molecular mechanism underlying this phenom-
enon is to date still unclear. Earlier studies suggested a crucial role
for cellular 14.7K interacting proteins [8,9]. Among previously
identified candidate proteins, optineurin was reported to modulate
the anti-apoptotic effect of 14.7K [9,16]. As a component of the
TNFR1 complex, optineurin is furthermore involved in regulation
of NF-kB signaling by competing with IKKc for ubiquitinated
RIP1 [11,17]. In addition, a role for optineurin in endo- and
exocytotic vesicle trafficking has been demonstrated [12,18].
In this study, we aimed to understand the physiological
relevance of 14.7K-optineurin interaction in 14.7K-mediated
TNF-resistance. As optineurin is part of the TNFR1 complex,
we tested the hypothesis that both optineurin and 14.7K are upon
ligand binding recruited to TNFR1 and are essential for 14.7K-
mediated TNF-resistance.
14.7K is Part of TNFR1 Complex and Mediates Protection
Against TNF-induced Cytotoxicity
Immunoprecipitation of 14.7K-optineurin complexes were
performed in KB cells and stably transduced 14.7K expressing
variants thereof (designated KB/14.7K). Before immunoprecipi-
tation, cells were transfected with HA-tagged optineurin and 24
hours after transfection treated with 50 ng/mL TNF (Figure 1A)
or biotinylated TNF (Figure 1B) for 10 min or left untreated. Cell
lysates were subjected to immunoprecipitation with anti-HA
agarose or streptavidin-coupled agarose. To control specificity
when precipitating the ligand, 50 ng/mL biotin-TNF was added
in excess to cell lysates from unstimulated cells.
In Western blot analysis we showed that 14.7K, TNFR1 and
RIP1 coimmunoprecipitated with HA-tagged optineurin, indicat-
ing formation of a protein complex (Figure 1A). This result was in
good accordance with previous studies, describing optineurin as a
14.7K and RIP1 interacting protein [8,11]. Of note, formation of
the 14.7K-optineurin complex was also detectable without
stimulation while recruitment to the TNFR1 complex and
ubiquitination of TNFR1-associated RIP1 were dependent on
TNF treatment. Interestingly, even though the predicted binding
sites of 14.7K and RIP1 were both located in the C-terminus of
optineurin, 14.7K obviously did not disturb interaction of
optineurin and RIP1 [10].
To further substantiate our findings and to exclude formation of
two independent protein complexes (cytosolic 14.7K-optineurin
complex on the one hand and a optineurin-RIP1-TNFR1
complex on the other hand) we also performed reverse immuno-
precipitations with biotin-labeled TNF and streptavidin-coupled
agarose (Figure 1B). Analogous to our previous experiments, we
precipitated 14.7K, RIP1 and TNFR1 together with biotinylated
TNF. In sum, these results indicate formation of a ligand-inducible
complex at TNFR1 containing optineurin, 14.7K and RIP1.
Interestingly, we also detected a faint 14.7K-band in immunopre-
cipitations of untreated cells (Figure 1B, lane 3), raising the
possibility of a TNFR1-14.7K complex even in the absence of
TNF-induced recruitment of optineurin to TNFR1. Technically,
precipitation of this complex was feasible because 50 ng/mL of
biotinylated TNF were added to lysates of unstimulated cells as
specificity control. Therefore, optineurin-mediated recruitment is
potentially not an exclusive mechanism of 14.7K-association with
TNFR1 complex. It may rather constitute an additional route for
14.7K to TNFR1, possibly with the objective to modulate
signaling pathways with optineurin involvement.
Non-protective 14.7K PM Exhibits Loss of Interaction with
Optineurin
Several studies characterized 14.7K as a general inhibitor of
TNF-induced cytolysis [7,14,15]. Structural integrity of the
protein seems essential as the C-terminal point mutation C119S,
referred to as 14.7K PM, resulted in loss of function [14]. In good
accordance with previous data, H1299 and KB cells expressing
wild-type 14.7K were resistant to TNF-mediated cytotoxicity even
in the presence of cycloheximide (CHX) as sensitizing agent,
displaying only about 20% apoptotic cells when challenged with
TNF in doses far exceeding physiological levels (Figure 2A). In
sharp contrast, 14.7K PM expressing cells of both cell lines were as
susceptible as untransduced parental cell lines and displayed about
80% cytolysis. These findings were also reflected by detectable
caspase-8 activation in H1299 parental cells and subsequent
poly(ADP-ribose)-polymerase 1 (PARP) cleavage (Figure 2B). Both
events were absent in H1299/14.7K cells.
In order to examine a possible correlation between optineurin-
14.7K interaction and TNF-resistance, we analyzed in a first
approach the binding of 14.7K and 14.7K PM to optineurin in a
mammalian-two-hybrid assay, using an optineurin construct
(OPTN D1-394) with the identified 14.7K binding site [8] as bait
(Figure 3A). As expected, 14.7K interacted with OPTN D1-394 as
measured by reporter luciferase activity. However, the non-
protective 14.7K PM (see also Figure 2) failed to induce luciferase
activity, a clear indicator for loss of optineurin binding.
These predicted interactions were confirmed in coimmunopre-
cipitation experiments (Figure 3B). Cell lysates from HEK293 cells
transfected with HA-tagged optineurin and 14.7K or 14.7K PM
were subjected to immunoprecipitation with anti-HA agarose.
14.7K was detectable after precipitation of HA-tagged optineurin,
thereby confirming interaction of the two proteins. However, due
to low expression levels of 14.7K PM, assessment of total 14.7K or
14.7K PM expression was only achieved by immunoprecipitation
of these proteins from the cell lysate. Consequently, to exclude the
possibility that weak expression of 14.7K PM may be causative for
the observed loss of optineurin interaction, we also performed a
reverse coimmunoprecipitation in HEK293 cells transfected with
HA-tagged 14.7K and wildtype optineurin (Figure 3B). In this
approach, we achieved similar precipitation levels of 14.7K and
14.7K PM. Cell lysates were subjected to immunoprecipitation
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with anti-HA-agarose and precipitates immunoblotted for HA-
14.7K and optineurin. Both experimental setups verified the non-
protective 14.7K PM to be defective in optineurin-binding, which
was in good accordance with our previous results. At this point,
our data suggested a fundamental role for the TNFR1-associated
14.7K-optineurin complex in mediating TNF-resistance.
Generation and Characterization of 14.7K Mutants
The failure of 14.7K PM to protect against TNF could be
attributed to mutation-related loss of function of 14.7K PM or
absence of its interaction partner optineurin. In consequence,
individual characterization of the contribution of optineurin and
14.7K to TNF-resistance required generation of suitable 14.7K
mutants, ideally with no intrinsic protection against TNF but
conserved optineurin binding. Accordingly, we performed a
systematic mutagenesis and sequentially replaced five amino acids
by a Flag-tag sequence (DYKDE), covering the entire 14.7K gene
(Figure 4). All generated 14.7K mutants were characterized
regarding their capability to bind optineurin using a mammalian-
two-hybrid screen (Figure 5A). With one exception, mutations in
the C-terminus resulted in loss of optineurin binding, thereby
confirming earlier studies stating that the C-terminal region was
essential for protein-protein interactions [14,19]. Consequently, to
maximize the probability to obtain a structural integer 14.7K
mutant without TNF-resistance, we choose two N-terminal
mutants, designated as ‘‘14.7K mut 1’’ and ‘‘14.7K mut 3’’.
Optineurin-14.7K interaction of the selected mutants was
additionally validated in coimmunoprecipitation experiments
(Figure 5B).
Optineurin Binding to 14.7K is not Sufficient to Mediate
TNF-resistance
Selected 14.7K mutants with retained optineurin binding
capacity were stably expressed in H1299 cells and assessed for
TNF-protection (Figure 6A). 14.7K mut 1 exhibited a comparable
degree of protection as 14.7K wild-type protein. This made the
construct unfeasible for tracing back TNF-resistance to either
14.7K or 14.7K-optineurin complex and it was therefore
excluded. However, 14.7K mut 3 failed to rescue cells after
challenge with TNF although optineurin binding was retained,
making it a suitable candidate for further investigations.
Again, results from cytotoxicity assays were concordant with
results of caspase activation analysis. Following TNF-stimulation,
H1299 and H1299/14.7K mut 3 cells showed cleavage of initiator
and effector caspases as correlate for ongoing apoptotic cell death
(Figure 6B), which was not detectable in H1299/14.7K cells.
These findings were consistent with the observations from
cytotoxicity assays shown in Figure 2A and with previous studies,
demonstrating a blockade of caspase-8 cleavage in 14.7K
expressing cells [4]. Together, these results indicated that
interaction of 14.7K with optineurin is surprisingly not involved
in inhibition of caspase-8 activation.
Optineurin Knockdown does not Affect 14.7K-mediated
Protection Against TNF
So far, our results suggested that optineurin is dispensable for
TNF-resistance mediated by 14.7K. However, it had to be
excluded that lost protection of 14.7K mut 3 is due to the N-
terminal exchange of five amino acids and resulting impaired
structural integrity, in case of the 14.7K protein a commonly
encountered phenomenon [14].
We therefore used siRNA-mediated knockdown of optineurin to
investigate the impact on 14.7K-mediated TNF-resistance. Effi-
cacy and duration of siRNA-mediated optineurin knockdown was
measured and lasted at least over a period of 6 days (Figure 7A).
H1299 and H1299/14.7K cells treated with optineurin-specific or
control siRNA were challenged in a cytotoxicity assay with
increasing amounts of TNF in the presence of the sensitizing agent
CHX (Figure 7B). Knockdown efficacy of siRNA transfection was
ensured by Western blotting. H1299 cells expressing 14.7K were
protected against TNF-mediated cytotoxicity in the presence and
absence of optineurin, excluding an essential contribution of
Figure 1. Optineurin and 14.7K are recruited to TNFR1 complex. Parental KB cells and KB cells stably expressing 14.7K were transfected with
30 mg HA-tagged optineurin. 24 hours after transfection, cells were challenged with 50 ng/mL TNF (A) or biotinylated TNF (B) for 10 min or left
untreated. Proteins associated with HA-tagged optineurin (A) or biotinylated TNF (B) were analyzed together with the corresponding lysates for the
presence of TNFR1, optineurin, 14.7K and RIP1.
doi:10.1371/journal.pone.0038348.g001
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optineurin to the protective effect. Although knockdown of
optineurin led to a slight, statistically not significant (p.0.05,
Kruskal-Wallis test) loss of cell viability upon TNF treatment
(Figure 7B, approx. 9% in H1299 parental cells and 13% in
H1299/14.7K cells), wildtype 14.7K expressing cells were clearly
protected against cytotoxic effects of TNF in the absence of
optineurin. As TNF cytolysis was evident in H1299 parental cells
in absence of optineurin, it was likely that this molecule is not
involved in TNFR1-associated apoptotic mechanisms either.
As we noticed presumably optineurin-independent formation of
TNFR1-14.7K complexes in our previous immunoprecipitation
experiments (Figure 1B), we next addressed the role of optineurin
as a crucial adaptor to convey 14.7K to TNFR1 complex.
Immunoprecipitation experiments in KB cells treated with
optineurin-specific siRNA and stimulated with biotin-labeled
TNF (Figure 7C) demonstrated 14.7K-recruitment to TNFR1
complex independent of optineurin expression and TNF-stimula-
tion. The faint protein band of 14.7K in the last lane of the
immunoprecipitation group is likely to be due to lower precipi-
tation of TNFR1 in that sample. Knockdown efficacy of
optineurin was again assured by Western blotting.
Together, these results strengthened our hypothesis of TNF-
and optineurin independent TNFR1-14.7K protein complex
formation.
The TNF-resistant phenotype of optineurin knockdown cells
was also confirmed by the persistent blockade of TNFR1
internalization. Confocal microscopy of H1299 cells stably
transfected with 14.7K wild-type protein exhibited blocked
TNFR1 internalization, irrespective of the absence or presence
Figure 2. 14.7K protects H1299 and KB cells from TNF-induced apoptosis. (A) H1299 and KB cells expressing either wild-type 14.7K (open
squares) or 14.7K PM (black triangles) or untransfected cells (open circles) were seeded in triplicates in 96-well plates. The next day, cells were
sensitized with cycloheximide (H1299 cells 12.5 mg/mL, KB cells 2.5 mg/mL) and treated with increasing amounts of TNF (H1299 cells 0.001–10 ng/mL,
KB cells 0.001–1000 ng/mL). Dead cells were removed by washing with PBS followed by staining of viable cells with crystal violet. (B) Caspase
activation was analyzed in CHX-sensitized (12.5 mg/mL for 1 hour) H1299 parental and H1299/14.7K cells. After stimulation with TNF for the indicated
time, cells were harvested, lysed and subjected to Western blotting.
doi:10.1371/journal.pone.0038348.g002
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Figure 3. 14.7K PM fails to interact with optineurin. (A) HEK293 cells were transfected with 200 ng of either wild-type 14.7K or 14.7K PM cloned
in pAD expression plasmid and OPTN D1-394 along with the reporter luciferase firefly (pFR-luc) and a transfection control luciferase renilla (pRL-TK).
48h after transfection, luciferase activity in cell lysates was measured. The relative luciferase activities are expressed as ratio of the reporter luciferase
to the transfection control (n = 3). (B) For immunoprecipitation experiments, HEK293 cells were transfected with 5 mg of either wild-type 14.7K or
14.7K PM along with OPTN D1-394 cloned in the expression plasmid pQCXIP (left panel). 48 hours after transfection cell lysates were subjected to
immunoprecipitation using anti-HA agarose. Immunoprecipitates were analyzed by Western blotting using HA and 14.7K antibodies. Detection of
14.7K in corresponding lysates required immunoprecipitation with 14.7K antibody due to low expression level of 14.7K PM. To achieve comparable
levels of 14.7K and 14.7K PM (right panel), HEK293 cells were transfected with 5 mg HA-tagged wildtype 14.7K or 15 mg of HA-tagged 14.7K PM along
with 5 mg optineurin.
doi:10.1371/journal.pone.0038348.g003
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of optineurin (Figure 8). Taken together, a significant contribution
of optineurin to the 14.7K-mediated protective effect was unlikely.
Optineurin is not Required for TNFR1-associated NF-kB
Activation
As ligand binding to TNFR1 under physiological conditions
primarily induces proinflammatory NF-kB signaling, we conse-
quently examined the effects of optineurin knockdown on
activation of NF-kB inhibitor IkBa. Phosphorylation of IkBa acts
as a trigger for its degradation, leading to nuclear translocation of
p65/p50 heterodimers [20]. To determine the effect of optineurin
on IkBa phosphorylation in 14.7K expressing cells, H1299 and
H1299/14.7K cells were transfected with optineurin-specific or
control siRNA. 48 hours after transfection cells were treated with
TNF for 5 min and cell lysates were analyzed by Western blotting
with antibodies specific for IkBa and phospho-IkBa (Figure 9A).
Knockdown efficacy was again confirmed by Western blotting.
Stimulation of cells with TNF resulted in rapid phosphorylation of
IkBa in all cell lines, irrespective of siRNA transfection. These
findings were complemented by measurement of the activated NF-
kB subunit phospho-p65 and the NF-kB-controlled target gene IL-
8. Phosphorylation and degradation of IkBa leads to the release
and phosphorylation of NF-kB subunit p65 which in return
translocates into the nucleus to initiate the production of pro-
inflammatory cytokines such as IL-8 [20]. In good agreement with
unaltered IkBa phosphorylation, neither phosphorylation of NF-
kB subunit p65 (Figure 9B) nor production of IL-8 (Figure 9C) was
affected by knockdown of optineurin. As reported earlier, the
activation of NF-kB pathway was not affected by presence or
absence of 14.7K [4]. Together, these observations suggest that
neither absence of optineurin nor presence of 14.7K did alter NF-
kB activation. In the light of our findings, optineurin was neither
essential for the antiapoptotic effect of 14.7K nor for the activation
of NF-kB pathway in 14.7K expressing cells.
Discussion
Immune escape mechanisms are of vital importance for
intracellular pathogens. In this study, we report association of
optineurin and 14.7K with TNFR1 complex. The protective effect
of 14.7K against TNF-mediated cytolysis is solely dependent on
presence of functional 14.7K, not on interaction with its binding
partner optineurin. Furthermore, recruitment of 14.7K to TNFR1
does not affect TNF-induced proinflammatory NF-kB signaling.
The phenomenon of 14.7K-mediated protection against TNF
was investigated in an earlier study of our group. Essentially,
14.7K prevents TNFR1 internalization and thereby abolishes
subsequent formation of the death inducing signaling complex,
whereas proinflammatory TNFR1 signaling involving RIP1 and
TRAF2 was not affected [4]. At that time we failed to identify the
molecular point of 14.7K action, especially as recruitment of
14.7K to TNFR1 could not be demonstrated. We therefore
suggested an indirect mechanism of interference, probably
involving cellular 14.7K interacting proteins. However, when
analyzing caspase-8 activation in lysates from H1299 cells
expressing 14.7K (Figure 2B and 6B), we found severely impaired
processing of the full length form (p55/53) to the first intermediate
product (p43/41) after TNF stimulation. Interestingly, this pointed
to a mechanism acting directly at TNFR1 complex as initial
cleavage of caspase-8 cleavage occurs receptor-associated
[4,6,21,22].
As our previous analysis of magnetically labeled TNRF1-
containing endosomes did unfortunately not allow identification of
14.7K at TNFR1 level, we opted for an alternative experimental
approach and performed immunoprecipitation experiments.
Technically, detection of 14.7K expression in previous experi-
ments was handicapped by restricted availability and limited shelf
life of 14.7K antibodies used in studies over 20 years ago. This was
further aggravated by the lack of commercially available, highly-
sensitive antibodies. To overcome these issues, we used a custom-
made polyclonal antibody from GST-14.7K immunized rabbits.
In immunoprecipitation experiments, we were for the first time
able to demonstrate a ligand-inducible association of 14.7K,
optineurin and TNFR1 (Figure 1). Interestingly, interaction of
14.7K and optineurin occurred even in the absence of TNF. This
may reflect an artifact caused by supraphysiological expression
levels of optineurin, but nevertheless provides evidence for a direct
interaction of both molecules in a cellular system. These findings
extended results from our previous study, which suggested an
indirect interference of 14.7K involving cellular binding proteins.
A yeast-two-hybrid screen identified optineurin as a 14.7K
interacting protein [9], and this molecule was also found in a
complex of TNFR1 and ubiquitinated RIP1 [11]. It was therefore
tempting to speculate that optineurin may act as an adaptor
molecule to convey 14.7K to activated TNFR1 complex,
especially as our data from the mammalian-two-hybrid assay
(Figure 3A) and coimmunoprecipitations (Figure 3B) confirmed
predictions from earlier studies [9,11].
Figure 4. Generation of sequential mutants of 14.7K. The top row gives the names of the generated mutants. The bottom row displays the
amino acid sequence of 14.7K replaced by a five amino acid Flag-tag (DYKDE). The arrow points to the C119S substitution, which was designated as
14.7K PM.
doi:10.1371/journal.pone.0038348.g004
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Upon treatment with TNF, we observed formation of a protein
complex containing TNFR1, ubiquitinated RIP1, optineurin and
14.7K. Integration of optineurin into the TNFR1 signaling
complex has been demonstrated before [11], suggesting that
ubiquitinated RIP1 acts as an adaptor protein for optineurin.
Detection of RIP1 in its ubiquitinated form is indicative for
ongoing early events in NF-kB activation.
Since association of optineurin with the TNFR1 complex was
unaffected by the presence of 14.7K, the latter apparently does not
interfere with optineurin recruitment and RIP1-optineurin bind-
ing (Figure 1A). Of note, binding sites for ubiquitinated RIP1 and
14.7K were both mapped to the C-terminus of optineurin [8] but
seemingly did not interfere with each other as otherwise TNFR1
recruitment of one of the components is likely to be impaired. Still,
it was possible that the pool of immunoprecipitated optineurin
Figure 5. Identification of 14.7K-mutants interacting with optineurin. (A) HEK293 cells were transfected with mutants of 14.7K cloned in
pCMV-AD and OPTN D1-394 (pCMV-BD) along with the reporter luciferase firefly (pFR-luc) and a transfection control luciferase renilla (pRL-TK). 48 h
after transfection cell lysates were prepared for luciferase measurement. The relative luciferase activities are indicated as ratio of reporter luciferase to
transfection control (n = 3). (B) HEK293 cells were transfected with either 5 mg 14.7K wild-type or indicated derivates along with 5 mg HA-tagged
OPTN D1-394 and subjected to immunoprecipitation using HA-agarose. Immunoprecipitates were analyzed for optineurin-associated proteins by
Western blotting. Detection of 14.7K PM from the corresponding lysates required immunoprecipitation to overcome low expression levels.
doi:10.1371/journal.pone.0038348.g005
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contained optineurin-RIP1-TNFR1 complexes as well as cytosolic
optineurin-14.7K complexes. To circumvent this, we precipitated
biotinylated TNF bound to TNFR1, thereby excluding non-
TNFR1-associated cytosolic protein complexes (Figure 1B). A
distinct recruitment of 14.7K to TNFR1 was found in a TNF-
dependent manner and interaction of 14.7K with TNFR1
complex was again confirmed. Interestingly, even in the absence
of TNF and therefore missing ligand-induced optineurin recruit-
ment to TNFR1, a small amount of TNFR1 complex associated
14.7K was detectable (Figure 1B). This finding was verified in
another immunoprecipitation experiment (Figure 7C), in which
after siRNA-mediated knockdown of optineurin TNFR1-14.7K
interaction was still observed. Together, these data indicated that
optineurin-14.7K interaction is not a canonical prerequisite for
recruitment of 14.7K to TNFR1.
To further investigate the role of 14.7K and optineurin
recruitment to TNFR1 after ligand binding, we took in a first
approach advantage of a previously established point mutation of
14.7K [14]. Loss of protein function due to a C119S substitution
resulted in apoptotic cell death after TNF exposure (Figure 2), with
activation of initiator and effector caspases, a hallmark of
apoptosis. TNF-sensitivity of 14.7K PM expressing cells is in line
with previous studies [4,14], and has been attributed to a mutation
related loss of function.
Interestingly, we recognized absent optineurin binding in TNF-
sensitive 14.7K PM cell lines (Figure 3A–B), supporting our
hypothesis for a crucial role of optineurin-14.7K complex in
mediating TNF-resistance.
Unfortunately, 14.7K PM has several experimental limitations.
The protein is reported to be unstable and therefore in Western
blot analysis barely detectable, as substitution of the cysteine
residue 119 disrupts sulfide bonds and affects zinc binding
properties [19]. This tremendously complicates assessment of
protein expression, and distinguishing between low protein levels
and loss protein functions as correlate for the sensitivity towards
TNF is difficult. Additionally, 14.7K PM does not allow
discrimination between mutation-related loss of function or loss
of optineurin binding as cause for TNF-sensitivity. As deletion of
amino acids almost inevitably resulted in loss of protein function
[14], our experimental approach based on systematic replacement
of five amino acids with a Flag-epitope (DYKDE) (Figure 4).
Analyzing optineurin binding of the generated 14.7K mutants
revealed that amino acid substitutions in the C-terminus were
accompanied with loss of binding capacity (Figure 5). This is in
agreement with earlier data stating a crucial role of the C-terminus
for structural integrity of 14.7K [14,19]. The only exception
seemed to be ‘‘14.7K mut 21’’, with apparently conserved
optineurin interaction in the mammalian-two-hybrid system.
However, we were repeatedly not able to confirm the predicted
interaction in immunoprecipitation experiments (data not shown),
therefore an assay-derived artifact cannot be ruled out.
Pure physical interaction of 14.7K and optineurin was not
sufficient to protect against TNF, as in cytotoxicity assays H1299/
14.7K mut 3 cells died upon TNF-treatment in a dose-dependent
manner (Figure 6A). Cell death involved cleavage of caspase-8 and
caspase-3, thereby triggering the apoptotic pathway (Figure 6B).
Finally, a substantial role for optineurin in 14.7K-mediated TNF-
protection was ruled out in siRNA experiments. Even at not
detectable optineurin levels in Western blot, 14.7K expressing cells
were resistant to TNF (Figure 7B) and still exhibited blocked
TNFR1 internalization (Figure 8).
Beside induction of cell death, TNFR1 signaling is under
physiological circumstances mainly proinflammatory, especially
through activation of the NF-kB pathway. Therefore, after
excluding optineurin as a key player in 14.7K-mediated TNF-
resistance and as previous studies provided evidence for a role of
optineurin in NF-kB signaling [11,17,23], we investigated the
effects of optineurin-14.7K interaction in this pathway. Interest-
ingly, Sudhakar and colleagues characterized optineurin itself as a
target gene of NF-kB [23,24]. Optineurin recruitment to TNFR1
has been postulated to negatively regulate TNF-induced NF-kB
activation due to competition of optineurin with the regulatory
Figure 6. Optineurin binding to 14.7K is not sufficient for protection against TNF. (A) H1299 cells expressing indicated 14.7K variants were
seeded in triplicates in 96-well plates and treated with 12.5 mg/mL CHX and increasing amounts of TNF (0.001–10 ng/mL) the next day. Dead cells
were removed by washing with PBS followed by staining of viable cells with crystal violet. (B) H1299 cells expressing either 14.7K, 14.7K mut 3 or
untransfected cells were treated (right panel) or not (left panel) with CHX (12.5 mg/mL) followed by stimulation with 20 ng/mL TNF for 5 h. Lysates
were analyzed by Western blotting with caspase-8 and caspase-3 antibodies. Tubulin was used as loading control.
doi:10.1371/journal.pone.0038348.g006
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Figure 7. 14.7K-mediated protection against TNF cytotoxicity and recruitment to TNFR1 is independent from endogenous
optineurin. (A) Knockdown efficacy of optineurin-specific siRNA was confirmed by Western blotting and lasted at least for 6 days (B) H1299 parental
or 14.7K expressing cells transfected with 100 pmol optineurin specific or control siRNA were seeded in 96-well plates and after 48 h challenged with
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subunit of IkB kinase (NF-kB essential modulator, NEMO) for
ubiquitinated RIP1 [11]. Nagabhushana and colleagues proposed
a more detailed mechanism with optineurin as adaptor molecule
for deubiquitinases like CYLD to terminate NF-kB signaling by
inactivation of RIP1 [17]. Though, optineurin might be part of a
negative feed back loop for proinflammatory TNFR1 signaling.
Consequently, downregulation of endogenous optineurin should
cause higher levels of phospho-p65 and IL-8 due to prolonged NF-
kB signaling. However, in our experiments knockdown of
optineurin did not result in sustained NF-kB signaling as measured
by comparable amounts of IL-8 production and p65 phosphor-
ylation in optineurin-naı¨ve or knockdown cells (Figure 9B–C). In
addition, with respect to IkBa phosphorylation we could not
detect enhanced NF-kB activation in optineurin knockdown cells
(Figure 9A) as reported previously [23]. The fact that rapid IkBa
phosphorylation as indicator for early steps in NF-kB activation
occured in 14.7K protected cells with blocked TNFR1 internal-
ization is consistent with earlier reports claiming activation of this
proinflammatory pathway at plasma membrane level in the
absence of receptor internalization [4,6,21].
Together, our results did not point towards a regulatory role of
optineurin in TNFR1-induced NF-kB activation. This discrepancy
may arise from cell line specific properties in NF-kB signaling and
different experimental design. Sudhakar et al. analyzed NF-kB
activation using a reporter gene assay [23], whereas we measured
endogenous IL-8 production. The latter might be also regulated
through complementary mechanisms or overlapping regulatory
feedback loops.
In summary, ligand-inducible association of optineurin and
14.7K with TNFR1 complex is not linked to 14.7K-mediated
TNF-resistance. Protection against cytotoxic effects exclusively
depends on expression of functional 14.7K, whereas interaction
with optineurin in this regard is dispensable. Concerning
activation of the NF-kB pathway, we found that recruitment of
14.7K to TNFR1 does not impair TNF-induced NF-kB activa-
tion. However, further studies are needed to clarify the impact of
optineurin-14.7K complex on TNFR1-induced NF-kB signaling,
especially in context of viral infection.
Perspectively, understanding the precise molecular mechanism
underlying 14.7K-mediated apoptosis blockade could be ex-
ploited as a therapeutic strategy for treatment of disorders
associated with increased TNF-levels such as rheumatoid
arthritis and Crohn’s disease. In this context, blocking
deleterious TNF-effects could control cytokine-induced collateral
damage in inflammed tissue.
Materials and Methods
Cell Culture, Plasmid and siRNA Transfections
H1299 cells were obtained from LGC Standards GmbH
(Wesel, Germany), HEK293 and KB cells were purchased from
the German collection of microorganisms and cell cultures
(Leibnitz Institute, Braunschweig, Germany). H1299, HEK293
and KB cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen, Carlsbad, USA) supplemented
with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/
mL streptomycin. Transient transfections of plasmids used
increasing amounts of TNF (0.001–1 ng/mL) in the presence of CHX (12.5 mg/mL). Cell viability was assayed by staining with crystal violet. Knockdown
of endogenous protein was confirmed by Western blotting. (C) Cells were seeded in a 10 cm culture plate, transfected with 600 pmol optineurin-
specific siRNA or control siRNA and treated with 50 ng/mL biotin-labeled TNF 24 hours after transfection. Proteins associated with biotinylated TNF
were analyzed for the presence of TNFR1 and 14.7K. Cell lysates confirmed efficient knockdown of optineurin in the corresponding samples.
doi:10.1371/journal.pone.0038348.g007
Figure 8. Blockade of 14.7K-mediated TNFR1 internalization persists in optineurin-knockdown cells. Confocal microscopy of H1299
parental or H1299 14.7K expressing cells 48 h after transfection with 100 pmol optineurin-specific or control siRNA. Cells were labeled with biotin-
TNF/strepavidin-FITC complexes for one hour on ice and analyzed immediately for TNFR1 internalization (pictures A, C, E, G) or shifted to 37uC for
another hour before microscopy (pictures B, D, F, H). Pictures were acquired using a Zeiss LSM 510, magnification 630-fold. A representative
experiment of three independent experiments is shown.
doi:10.1371/journal.pone.0038348.g008
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polyethyleneimide (Polysciences, Warrington, USA). In brief,
cells were seeded at 80% confluency overnight. Before
transfection, growth medium was replaced with DMEM without
fetal bovine serum and antibiotics. Polyethyleneimide stock
solution (1 mg/mL) was mixed with plasmid DNA at a 3:1 ratio
in 1 mL DMEM and incubated for 20 min at room temper-
ature before added to the cells. Cells were incubated for 4–6
hours before medium was replaced by growth medium
supplemented with 10% fetal bovine serum, 100 U/mL
penicillin and 100 mg/mL streptomycin.
Knockdown of optineurin was performed using specific siRNAs
(Dharmacon, Lafayette, USA). Briefly, cells were seeded in 6-well
plates (1.56105 per well) and transfected with 100 pmol of specific
or control siRNA using Lipofectamine 2000 transfection system
(Invitrogen, Carlsbad, USA) according to manufacturer’s instruc-
tions. Two days post transfection, knockdown efficacy was
determined by Western blotting. Subsequent cytotoxicity assays
were performed in 96-well plates.
Retroviral Transfections of 14.7K cDNAs
H1299 and KB cells were transduced with pQCXIP (Clontech,
Cambrex, USA) expressing 14.7K or 14.7K mutants and the
packaging vector pCL10A1 (Imgenex Retromax System, Biomol,
Hamburg, Germany), essentially as described elsewhere [6]. After
2–3 rounds of serial transductions, transduced cells were selected
using puromycin (3 mg/mL).
Antibodies
Rabbit polyclonal anti-optineurin (Abcam, Cambridge, UK),
anti-HA-antibody (Dianova, Hamburg, Germany), anti-a-Tubulin
(Santa Cruz, CA, USA), anti-RIP1 (BD Biosciences, Heidelberg,
Germany), anti-TNFR1, anti-Caspase-8 and anti-Caspase-3 were
obtained from Cell Signaling (Beverly, MA, USA). Anti-14.7K is a
selfmade polyclonal antibody from GST-14.7K immunized rabbits
(Immunoglobe, Himmelstadt, Germany). HRP-conjugated anti-
mouse and anti-rabbit antibodies were purchased from Biorad
(Munich, Germany).
Figure 9. 14.7K and optineurin do not affect NF-kB activation. H1299 parental or 14.7K expressing cells were transfected with 100 pmol
optineurin-specific siRNA or control siRNA. Knockdown of optineurin was confirmed by Western blotting. (A) Cells were challenged with TNF (20 ng/
mL) for 5 min. Cell lysates were subjected to Western blot analysis using antibodies specific for IkBa, phospho-IkBa and tubulin (loading control). (B)
Cells were challenged with TNF (20 ng/mL) for 10 minutes. Cell lysates were subjected to phospho-p65 ELISA and analyzed at OD 450 nm. (C) Cells
were challenged with TNF (20 ng/mL) for 24 hours. Supernatants were subjected to IL-8 ELISA. n.d. = not detectable.
doi:10.1371/journal.pone.0038348.g009
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Expression Vectors and Plasmid Construction
14.7K mutants were generated using the PCR-based ‘‘Quick-
Change’’ site-directed mutagenesis kit (Stratagene, Santa Clara,
USA), sequentially replacing five amino acids by a Flag-tag
sequence (DYKDE). 14.7K PM was generated as described
previously [4]. Expression of 14.7K constructs used the pQCXIP
vector system (BD Biosciences).
For the mammalian-two-hybrid screen 14.7K constructs were
cloned into pCMV-AD vector (Stratagene) in frame with a N-
terminal p65-tag. Truncated OPTN D1-394 was generated by
PCR (primers: forward 59-GAA TTC ATG AAG CTT CTG
CAA GAA CAT AAT AAT G-39, reverse 59-GTC GAC TTA
CGT GCC AGT GGA GAC TGT TC-39) and cloned into
pCMV-BD vector with a N-terminal Gal4-tag. For immunopre-
cipitations, HA-tagged or untagged variants of 14.7K and
optineurin were expressed using the pQCXIP vector system. Full
length optineurin was kindly provided by Dr. Stephen Ferguson
(Robarts Research Institute, London, UK).
Mammalian-two-hybrid Assay
The mammalian-two-hybrid assay was purchased from Strata-
gene and performed according to manufacturer’s instructions.
Briefly, 46105 HEK293 cells grown on 6-well plates were
transfected with 200 ng of pCMV-AD and pCMV-BD containing
OPTN D1-394 or a 14.7K construct. pFR-Luc was cotransfected
(1200 ng) as reporter plasmid. Luciferase activity was measured
with a commercial assay (Dual-Luciferase reporter Assay System,
Promega, Mannheim, Germany) and normalized to Renilla
activity from cotransfected pRL-TK (Promega).
Coimmunoprecipitation
For coimmunoprecipitation experiments of optineurin and
14.7K, HEK293 cells (36106 cells per 10 cm dish) were
transfected with 5 mg of OPTN-HA and 14.7K constructs. For
coimmunoprecipitation experiments of HA-tagged 14.7K and
14.7K PM with optineurin, HEK293 cells were transfected with
5 mg 14.7K and 5 mg optineurin contructs. To achieve equal
expression levels of HA-tagged 14.7K and 14.7K PM, 15 mg of
14.7K PM construct was transfected along with optineurin
construct. Cells were harvested in lysis buffer containing protease
inhibitor cocktail (complete EDTA free, Roche, Mannheim,
Germany) and incubated 20 min on ice. Samples were cleared
by centrifugation (26200006g, 15 min), and incubated with
40 mL of a 50% HA-agarose slurry (Sigma, Steinheim, Germany)
at 4uC overnight shaking overhead. After washing in lysis buffer,
agarose-bound proteins were elutated by incubation at 95uC in 26
Laemmli sample buffer (4% SDS, 10% 2-mercaptoethanol,
20% glycerol, 0.125 M Tris, pH8, 0.004% bromphenol blue).
Immunoprecipitation of 14.7K was performed by adding 1 mg
of specific antibody to the lysate, followed by incubation at 4uC
overnight shaking overhead. Protein G sepharose (GE Healthcare,
Uppsala, Sweden) was washed three times in lysis buffer and
40 mL of a 50% slurry were added for another 1–3 h and shaked
overhead. After washing with lysis buffer, sepharose-bound
proteins were eluted by incubation at 95uC for 5 min in 26
Laemmli sample buffer.
TNFR1 Internalization Assay
16105 H1299 cells were seeded on coverslips. Biotinylated TNF
and strepatvidin-FITC reagent (R&D Systems, Wiesbaden,
Germany) were mixed and incubated at roomtemperature for
60 min in the dark.
Cells were incubated with biotin-TNF/streptavidin-FITC-com-
plex for 60 min on ice in the dark. Cells were washed with ice-cold
PBS and placed into 37uC pre-warmed medium for another
60 min to allow receptor internalization. For analysis of TNF-
receptor endocytosis, cells were fixed with paraformaldehyde (2%
in PBS) for 15 min and prepared for immunfluorescence. For
analysis, a confocal laser scanning microscope was used (LSM 510
META, Zeiss).
Precipitation of TNFR1-complexes
For coimmunoprecipitation of TNFR1-complex proteins, KB
cells were seeded at a density of 16107 cells in a 15 cm dish and
transfected with 30 mg of OPTN-HA, using polyethyleneimide
transfection method (see above). 24 hours after transfection, cells
were stimulated with 50 ng/mL of unlabeled TNF (Knoll AG,
Ludwigshafen, Germany) or biotin-labeled TNF (R&D Systems,
Minneapolis, USA) for 10 min or left untreated. Cells were
washed with ice-cold PBS and harvested in lysis buffer containing
protease inhibitor cocktail (complete EDTA free, Roche, Mann-
heim, Germany). Cell lysates were incubated 20 min on ice and
cleared by centrifugation (26 200006g, 15 min). In case of
stimulation with unlabeled TNF, lysates were incubated with
40 mL of a 50% HA-agarose slurry (Sigma, Steinheim, Germany)
at 4uC overnight. In case of stimulation with biotin-TNF, 40 mL of
a 50% streptavidin-agarose slurry was added to the lysates. Lysates
from unstimulated cells supplemented with 50 ng/mL TNF or
biotin-TNF served as negative control. After washing in lysis
buffer, agarose-bound proteins were eluted by incubation at 85uC
for 15 min in 26 Laemmli sample buffer. In case of coimmuno-
precipitation of TNFR1-complex proteins in siRNA-optineurin
knockdown cells, KB cells were seeded at a density of 26106 in a
10 cm dish and transfected with 600 pmol optineurin-specific
siRNA or control siRNA. 24 hours after transfection, cells were
stimulated with 50 ng/mL biotin-labeled TNF for 10 min or left
untreated. Following procedures were performed as indicated
above.
Western Blotting
Cells were washed with ice-cold PBS, harvested in lysis buffer
supplemented with protease inhibitor cocktail and incubated
20 min on ice. Lysates were cleared by centrifugation (200006g,
20 min) and protein concentration was determined using Bradford
reagent (Biorad, Munich, Germany). Laemmli sample buffer was
added and samples were boiled for 5 min at 95uC. Proteins were
separated by sodiumdodecylsulphate-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to PVDF membranes
(Roche, Diagnostics, Indianapolis, USA). After blocking non-
specific binding sites by incubation in Tris-buffered saline
containing 0.1% Tween-20 and 5% dry milk, primary antibodies
of indicated specificity were added. Subsequent incubation with
horseradish peroxidase-conjugated secondary antibodies (Biorad)
allowed detection of protein bands using SuperSignal West
Substrate (Pierce, Bonn, Germany).
TNF Cytotoxicity Assays
Cells were seeded in a 96 well plate in triplicates (36104 cells/
well), pre-treated with cycloheximide (H1299 cells 12.5 mg/mL,
KB cells 2.5 mg/mL) and finally challenged with increasing
amounts of TNF (H1299 cells 0.001–10 ng/mL, KB cells
0.001–1000 ng/mL) (Knoll AG, Ludwigshafen, Germany) over-
night. In case of siRNA treatment cells were challenged with final
concentration of 1 ng/mL TNF. Vital cells were stained with
crystal violet (0.5% crystal violet, 4% formaldehyde, 30% ethanol,
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30 mM NaCl) and solved in 200 mL 30% acetic acid. Optical
density was analyzed at 595 nm in a photometer.
ELISA
Cells were seeded in 6-well plates (1.56105 per well) and
transfected with 100 pmol of specific or control siRNA using
Lipofectamine 2000 transfection system (Invitrogen, Carlsbad,
USA) according to manufacturer’s instructions. For IL-8 detection,
cells were treated 24 hours after transfection with 20 ng/mL TNF
for another 24 hours. Supernatants were harvested and subjected
to IL-8 ELISA (BD Biosciences, Heidelberg, Germany) according
to manufacturer’s instructions. For detection of phosphorylated
NF-kB subunit p65, cells were treated 48 hours after transfection
with 20 ng/mL TNF for 10 min, harvested and subjected to
phospho-p65 ELISA (Cell Signaling, Beverly, MA, USA) accord-
ing to manufacturer’s instructions.
Acknowledgments
We thank Gertrud Knoll, Elke Perthen and Maria Kurz for technical
assistance. We are also indebted to Andre´ Gessner for generous support
and discussion.
Author Contributions
Conceived and designed the experiments: WSB TH ME HW SS LK.
Performed the experiments: LK UH ME. Analyzed the data: WSB LK TH
ME. Contributed reagents/materials/analysis tools: SS TH HW WSB UH
ME. Wrote the paper: ME LK WSB.
References
1. Wong G, Tartaglia L, Lee M, Goeddel D (1992) Antiviral activity of tumor
necrosis factor is signaled through the 55-kDa type I TNF receptor. J Immunol
149: 3350–3353.
2. Burgert H, Blusch JH (2000) Immunomodulatory functions encoded by the E3
transcription unit of adenoviruses. Virus genes 21: 13–25.
3. Horton TM, Ranheim T, Aquino L, Kusher D, Saha S, et al. (1991) Adenovirus
E3 14.7 K protein functions in the absence of other adenovirus proteins to
protect transfected cells from tumor necrosis factor cytolysis. J Virol 65:
2629–2639.
4. Schneider-Brachert W, Tchikov V, Merkel O, Jakob M, Hallas C, et al. (2006)
Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel
immune escape mechanism. J Clin Invest 116: 2901–2913.
5. Mosselmans R, Hepburn A, Dumont JE, Fiers W, Galand P (1988) Endocytic
pathway of recombinant murine tumor necrosis factor in L-929 cells. J Immunol
141: 3096–3100.
6. Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S,
et al. (2004) Compartmentalization of TNF Receptor 1 Signaling: Internalized
TNF Receptosomes as Death Signaling Vesicles. Immunity 21: 415–428.
7. Gooding LR, Sofola IO, Tollefson AE, Duerksen-Hughes P, Wold WS (1990)
The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-
mediated cytolysis. J Immunol 145: 3080–3086.
8. Li Y, Kang J, Horwitz MS (1998) Interaction of an adenovirus E3 14.7-
kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular
protein containing leucine zipper domains. Mol Cell Biol 18: 1601–1610.
9. Horwitz MS (2004) Function of adenovirus E3 proteins and their interactions
with immunoregulatory cell proteins. J Gene Med Suppl 1: S172–S183.
10. Swarup G, Nagabhushana A (2010) Optineurin, a multifunctional protein
involved in glaucoma, amyotrophic lateral sclerosis and antiviral signalling.
J Biosci 35: 501–505.
11. Zhu G, Wu C-J, Zhao Y, Ashwell JD (2007) Optineurin negatively regulates
TNFalpha-induced NF-kappaB activation by competing with NEMO for
ubiquitinated RIP. Curr Biol 17: 1438–1443.
12. Bond LM, Peden AA, Kendrick-Jones J, Sellers JR, Buss F (2011) Myosin VI
and its binding partner optineurin are involved in secretory vesicle fusion at the
plasma membrane. Mol Biol Cell 22: 54–65.
13. Park B, Ying H, Shen X, Park J-S, Qiu Y, et al. (2010) Impairment of Protein
Trafficking upon Overexpression and Mutation of Optineurin. PLoS ONE 5:
e11547.
14. Ranheim TS, Shisler J, Horton TM, Wold LJ, Gooding LR, et al. (1993)
Characterization of mutants within the gene for the adenovirus E3 14.7-
kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol 67:
2159–2167.
15. Zilli D, Voelkel-Johnson C, Skinner T, Laster SM (1992) The adenovirus E3
region 14.7 kDa protein, heat and sodium arsenite inhibit the TNF-induced
release of arachidonic acid. Biochem Biophys Res Commun 188: 177–183.
16. Li H, Ao X, Jia J, Wang Q, Zhang Z (2011) Effects of optineurin siRNA on
apoptotic genes and apoptosis in RGC-5 cells. Mol Vis 17: 3314–3325.
17. Nagabhushana A, Bansal M, Swarup G (2011) Optineurin Is Required for
CYLD-Dependent Inhibition of TNFa-Induced NF-kB Activation. PLoS ONE
6: e17477.
18. Sahlender DA, Roberts RC, Arden SD, Spudich G, Taylor MJ, et al. (2005)
Optineurin links myosin VI to the Golgi complex and is involved in Golgi
organization and exocytosis. J Cell Biol 169: 285–295.
19. Kim HJ, Foster MP (2002) Characterization of Ad5 E3-14.7K, an adenoviral
inhibitor of apoptosis: structure, oligomeric state, and metal binding. Protein Sci
11: 1117–1128.
20. Hayden MS, Ghosh S (2008) Shared Principles in NF-kB Signaling. Cell 132:
344–362.
21. Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis
via two sequential signaling complexes. Cell 114: 181–190.
22. Schu¨tze S, Tchikov V, Schneider-Brachert W (2008) Regulation of TNFR1 and
CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 9:
655–662.
23. Sudhakar C, Nagabhushana A, Jain N, Swarup G (2009) NF-kappaB mediates
tumor necrosis factor alpha-induced expression of optineurin, a negative
regulator of NF-kappaB. PLoS ONE 4: e5114.
24. Mrowka R, Blu¨thgen N, Fa¨hling M (2008) Seed-based systematic discovery of
specific transcription factor target genes. FEBS J 275: 3178–3192.
E3-14.7K and Optineurin Recruit to TNFR-Receptor 1
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e38348
